4D pharma PLC (LBPS)

NASDAQ: LBPS · IEX Real-Time Price · USD
4.36 -0.13 (-2.90%)
Jan 18, 2022 4:00 PM EST - Market closed
Market Cap101.38M
Revenue (ttm)490,000
Net Income (ttm)-67.69M
Shares Out23.25M
EPS (ttm)-4.83
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume3,526
Open4.32
Previous Close4.49
Day's Range4.26 - 4.49
52-Week Range4.26 - 15.50
Beta2.90
Analystsn/a
Price Targetn/a
Earnings Daten/a

About LBPS

4D pharma plc, together with its subsidiaries, engages in the research, development, and production of live biotherapeutic products. The company develops therapeutic candidates, such as MRx0518; MRx-4DP000 for the treatment of asthma and COVID-19; MRx0029 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, including MRx1299 for solid tumors, MRx0005 for neurodegeneration, MRx0006 for rheumatoid arthritis, and MRx0002 for multip...

IndustryBiotechnology
Founded2014
CEODuncan Peyton
Employees92
Stock ExchangeNASDAQ
Ticker SymbolLBPS
Full Company Profile

Financial Performance

Financial Statements

News

4D pharma to Present at the H.C. Wainwright BioConnect Conference

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the ...

2 weeks ago - Business Wire

4D pharma appoints John Doyle as Chief Financial Officer

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the ...

2 weeks ago - Business Wire

4D Pharma Announces Positive Topline Results From Part a of Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the ...

1 month ago - Business Wire

4D pharma Presents Microbiome Analyses from Phase II Clinical Trial of Blautix® for IBS-C and IBS-D at Gastro 2021

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the ...

1 month ago - Business Wire

4D pharma to Participate in Jefferies London Healthcare Conference

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the ...

2 months ago - Business Wire

4D pharma to Participate in Jefferies Virtual Next Generation IBD Therapeutics Summit

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD, NASDAQ, LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the ...

3 months ago - Business Wire

4D pharma Presents Two Clinical Posters for Live Biotherapeutic MRx0518 at the European Society for Medical Oncology ...

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the ...

4 months ago - Business Wire

4D pharma to Participate in Upcoming Virtual Investor Conferences in September

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the ...

4 months ago - Business Wire

4D pharma Announces Two Presentations at European Society for Medical Oncology (ESMO) Congress 2021

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the ...

5 months ago - Business Wire

4D pharma Announces $30 Million Credit Facility with Oxford Finance

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the ...

5 months ago - Business Wire

4D pharma Announces Passing of Chief Financial Officer John Beck

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD, NASDAQ, LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the ...

5 months ago - Business Wire

4D pharma Announces Publication of Preclinical Research Showing Single Strain Megasphaera massiliensis improves activ...

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the ...

6 months ago - Business Wire

4D pharma to Participate in Ladenburg Thalmann Healthcare Conference

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the ...

6 months ago - Business Wire

4D pharma to Present at the Microbiome Movement Drug Development Summit

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the...

6 months ago - Business Wire

4D pharma To Stop Testing Asthma Med in COVID-19 Patients

4D pharma plc (NASDAQ: LBPS) has completed its target enrollment of 30 patients for Part A of its Phase 1/2 trial of MRx-4DP0004 in patients with partly controlled asthma. Following the completion of en...

7 months ago - Benzinga

4D pharma Completes Enrollment of Part A of the Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma and Provi...

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the ...

7 months ago - Business Wire

4D Pharma's Stock Shoots Higher on Positive Data from Irritable Bowel Syndrome Candidate

4D pharma plc (NASDAQ: LBPS) has announced additional positive data from its completed Phase 2 trial of LBP Blautix in subjects with irritable bowel syndrome with constipation (IBS-C) or with diarrhea (...

7 months ago - Benzinga

4D pharma Presents Additional Positive Results of Phase II Study of Blautix® for the Treatment of Irritable Bowel Syn...

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD; NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the...

7 months ago - Business Wire

4D pharma to Present Additional Data from Phase II Study of Blautix for the Treatment of Irritable Bowel Syndrome at ...

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the...

8 months ago - Business Wire

4D pharma Collaborates With Parkinson's UK to Establish Patient Advisory Board

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD; NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the...

9 months ago - Business Wire

Final Results for the year ended 31 December 2020

Leeds, UK, April 01, 2021 (GLOBE NEWSWIRE) -- 4D pharma plc (AIM: DDDD, NASDAQ: LBPS) (“4D”, the “Company” or, together with its subsidiaries, the “Group”), a pharmaceutical company leading the developm...

9 months ago - GlobeNewsWire

Completion of Merger With Longevity Acquisition Corporation and Admission of American Depositary Shares to Trading on...

LEEDS, United Kingdom--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD) ("4D" or the "Company"), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug ...

9 months ago - Business Wire

4D pharma Announces Completion of Merger With Longevity Acquisition Corporation

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (Nasdaq: LBPS; AIM: DDDD) ("4D pharma" or the "Company"), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel...

9 months ago - Business Wire

Longevity Acquisition Corporation Announces Results of Special Meeting of Shareholders

NEW YORK, March 18, 2021 /PRNewswire/ -- Longevity Acquisition Corporation (NASDAQ: LOAC) (the "Company"), a publicly-traded special purpose acquisition company, announced today the results of its speci...

10 months ago - PRNewsWire

4D Pharma Announces Private Placement

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD) ("4D" or the "Company"), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived...

10 months ago - Business Wire